MedTrace Logo

An Open Label Study in Patients With Advanced NSCLC With ABI-007(Abraxane) in Combination With Carboplatin

NCT00274443 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 250

Last updated 2019-11-12

No results posted yet for this study

Summary

This is an open-label dose escalation trial using ABI-007 plus carboplatin.

Conditions

  • Non-Small Cell Lung Cancer (NSCLC)

Interventions

DRUG

ABI-007 (Abraxane) and Carboplatin

ABI-007 plus Carboplatin will be administered intravenously over 30 minutes in cycles of 3 weeks

Sponsors & Collaborators

  • Celgene

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-03-01
Primary Completion
2007-06-01
Completion
2007-06-01

Countries

  • Russia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00274443 on ClinicalTrials.gov